The Weizmann Institute of Science bestowed its Weizmann Award upon Jeffrey Aronin in December of 2017 at a Chicago gala event. That award is given annually to recognize medical professionals who have dedicated their lives, science undertakings and philanthropic efforts for the benefit of improving the lives of those who desperately need those efforts. The Institute was established in 1949 and is world-renowned in scientific research and in the advancement of avenues of investigation to improve human health, understanding of diseases, keeping up-to-date on and sharing the latest scientific breakthroughs, and educating about and advancing science literacy in the public and in schools.
Jeffrey Aronin is the CEO and chairman of Paragon Biosciences, LLC and is also the founder, chairman and CEO of Paragon Pharmaceutical Capital, LLC, which is an investment firm which backs healthcare companies. He received a BA in Marketing in 1989 from Northern Illinois University.
Paragon Biosciences is a life sciences company that is innovation-based and mission-driven. It focuses on debilitating diseases that have no effective treatment and creates major advancements in pharmaceuticals and biotechnology that will result in the improvement of patient care for those who need those new and successful therapy options. The Paragon team has a relentless motivation to deliver the benefits of science to suffering patients by developing and commercializing new medicines and supporting healthcare innovators.
In addition to the 13 new medicines that Paragon has aided in bringing to market after getting Novel Drug Approvals through the Food and Drug Administration (FDA), a federal agency of the United States Department of Health and Human Services, Jeffrey Aronin is helping the growth of future innovation by the founding of MATTER, a Chicago healthcare start-up incubator with more than 200 companies that are in various development stages.